You are here: Industry Insights > Market News > Inovio signs deal with Japan’s Kaneka for COVID-19 vaccine manufacturing

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate

Neohesperidin

Advantame

Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench

Pharma and Food Grade, USP/FCC Neotame Sweetener E961

Trilobatin

Inovio signs deal with Japan’s Kaneka for COVID-19 vaccine manufacturing

expresspharmaDecember 04, 2020

Tag: INOVIO , kaneka , COVID-19 vaccine

Favorites

Japan’s Kaneka Corp has entered into a deal to manufacture Inovio Pharmaceuticals’ COVID-19 vaccine candidate, informed the company.

It did not disclose the terms of the agreement with Kaneka Eurogentec, a unit of the Japanese chemical company.

Inovio has also signed manufacturing deals with medical device maker Thermo Fisher Scientific among others, to increase the supply of the vaccine, which entered a mid-stage study last month.

The Phase 3 of the mid-to-late stage study is under a partial hold by the US Food and Drug Administration as it seeks more information, including details on a delivery device used to inject genetic material into cells.

Previous:Solutions For Powder Properties in Pharmaceuticals: Visit Micromeritics and Freeman technology in CPhI China 2020

Next:Indian pharma: Driving excellence in quality and patient centricity

Inovio signs deal with Japan’s Kaneka for COVID-19 vaccine manufacturing

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

You may like
More>>

Inovio signs deal with Japan’s Kaneka for COVID-19 vaccine manufacturing

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

You may likeMore>>

You may like
More>>